97P Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I–III non-small cell lung cancer with high-risk pathological factors

Pulmonary adenocarcinoma with high-risk pathological factors are known to be associated poor prognosis in early-stage non-small-cell lung cancer (NSCLC). Aumolertinib is a third-generation EGFR-TKI that has efficacy EGFR sensitive and resistant NSCLC. The of aumolertinib as adjuvant therapy resected stage I–III NSCLC remains unknown. Patients underwent completely pathologic micropapillary/solid component or without complex glands were enrolled. assigned group (group A): patients mutation-positive (exon 19 deletion L858R) received (110 mg daily), B (EGFR mutation positive) C negative unknown). Both observation for disease recurrence no was given. primary endpoint investigator assessed disease-free survival (DFS) safety evaluated. A total 115 micropapillary solid 70 (45 group, 25 B). 45 mutation-negative unknown C. At data cut-off, all have symptoms tumor continued aumolertinib, the 1-year DFS 100%. In B, 64% alive disease-free, 3 had within 1 year (1-year DFS: 88%). C, 89% 93%. Compared two treatment groups, recurrent ratio mutated higher than group. There grade ≥3 adverse events occurred during treatment, rash (15%), pruritus (27%), diarrhea (11%) mouth ulceration common events. This first report I-III factors. positive factor